Cargando…

652: IMPACT AND RECOVERY FROM COVID-19-RELATED DISRUPTIONS IN COLORECTAL CANCER SCREENING AND CARE: A SCENARIO ANALYSIS

Detalles Bibliográficos
Autores principales:	Puttelaar, Rosita van den, Lansdorp-Vogelaar, Iris, Hahn, Anne I., Rutter, Carolyn M., Levin, Theodore R., Zauber, Ann G., Meester, Reinier G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AGA Institute. Published by Elsevier Inc. 2022
Materias:	AGA Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9212616/ http://dx.doi.org/10.1016/S0016-5085(22)60383-4

Ejemplares similares

Impact and Recovery from COVID-19–Related Disruptions in Colorectal Cancer Screening and Care in the US: A Scenario Analysis
por: van den Puttelaar, Rosita, et al.
Publicado: (2023)

Projected long-term effects of colorectal cancer screening disruptions following the COVID-19 pandemic
por: Nascimento de Lima, Pedro, et al.
Publicado: (2023)

Unequal Recovery in Colorectal Cancer Screening Following the COVID-19 Pandemic: A Comparative Microsimulation Analysis
por: de Lima, Pedro Nascimento, et al.
Publicado: (2022)

Public Health Impact of Achieving 80% Colorectal Cancer Screening Rates in the United States by 2018
por: Meester, Reinier G S, et al.
Publicado: (2015)

783 IMPACT OF COVID-19 RELATED DISRUPTIONS TO COLORECTAL CANCER SCREENING PROGRAMS IN THREE COUNTRIES: A COMPARATIVE MODELLING STUDY
por: De Jonge, Lucie, et al.
Publicado: (2021)

Comparing the Cost-Effectiveness of Innovative Colorectal Cancer Screening Tests
por: Peterse, Elisabeth F P, et al.
Publicado: (2020)

The impact of the rising colorectal cancer incidence in young adults on the optimal age to start screening: Microsimulation analysis I to inform the American Cancer Society colorectal cancer screening guideline
por: Peterse, Elisabeth F. P., et al.
Publicado: (2018)

Impact of assumptions on future costs, disutility and mortality in cost-effectiveness analysis; a model exploration
por: Omidvari, Amir-Houshang, et al.
Publicado: (2021)

Risk‐stratified strategies in population screening for colorectal cancer
por: Lansdorp‐Vogelaar, Iris, et al.
Publicado: (2021)

An Evolutionary Algorithm to Personalize Stool-Based Colorectal Cancer Screening
por: van Duuren, Luuk A., et al.
Publicado: (2022)

Cost-effectiveness of a multitarget stool DNA test for colorectal cancer screening of Medicare beneficiaries
por: Naber, Steffie K., et al.
Publicado: (2019)

Potential global loss of life expected due to COVID-19 disruptions to organised colorectal cancer screening
por: Worthington, Joachim, et al.
Publicado: (2023)

1161: PERSISTENT IMMUNE CELL ABNORMALITIES IN THE INTESTINAL MUCOSA OF PATIENTS AFTER RECOVERY FROM COVID-19 INFECTION
por: Meringer, Hadar, et al.
Publicado: (2022)

811: IMPACT OF THE COVID-19 PANDEMIC ON FECAL IMMUNOCHEMICAL TESTING, COLONOSCOPY SERVICES, AND COLORECTAL NEOPLASIA DETECTION IN A LARGE UNITED STATES COMMUNITY-BASED POPULATION
por: Lee, Jeffrey K., et al.
Publicado: (2022)

Sa117 ABLATION OF REG4+ SUPPORT CELLS INDUCES A NOTCH-ASSOCIATED RECOVERY STATE IN THE MURINE COLONIC EPITHELIUM.
por: Wheeler, Timothy W., et al.
Publicado: (2021)

Cost-Effectiveness of Colonoscopy-Based Colorectal Cancer Screening in Childhood Cancer Survivors
por: Gini, Andrea, et al.
Publicado: (2019)

Sa002 IMPACT OF THE COVID-19 PANDEMIC ON A LARGE ORGANIZED COLORECTAL CANCER SCREENING PROGRAM BASED ON FECAL IMMUNOCHEMICAL TESTING AND OPPORTUNISTIC COLONOSCOPY
por: Levin, Theodore R., et al.
Publicado: (2021)

Optimizing colorectal cancer screening by race and sex: Microsimulation analysis II to inform the American Cancer Society colorectal cancer screening guideline
por: Meester, Reinier G. S., et al.
Publicado: (2018)

Colorectal Cancer Screening within Colonoscopy Capacity Constraints: Can FIT-Based Programs Save More Lives by Trading off More Sensitive Test Cutoffs against Longer Screening Intervals?
por: McFerran, Ethna, et al.
Publicado: (2022)

656: POST-VACCINATION SYMPTOMS AFTER A THIRD DOSE OF SARS-COV-2 MRNA VACCINATION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
por: Mujukian, Angela, et al.
Publicado: (2022)

653: PATIENTS WITH INFLAMMATORY BOWEL DISEASE HAVE IMPAIRED HUMORAL BUT PRESERVED CELLULAR RESPONSES TO SARS-COV-2 MRNA VACCINATION
por: Li, Dalin, et al.
Publicado: (2022)

Cost‐effectiveness of prophylactic hysterectomy in first‐degree female relatives with Lynch syndrome of patients diagnosed with colorectal cancer in the United States: a microsimulation study
por: Alblas, Maaike, et al.
Publicado: (2021)

654: A THIRD DOSE OF SARS-COV-2 VACCINE YIELDS HIGH ANTIBODY LEVELS COMPARED TO TWO DOSE VACCINATION SCHEDULE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
por: Quan, Joshua, et al.
Publicado: (2022)

Su1484: SEROLOGICAL RESPONSES TO SARS-COV-2 VACCINATION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A PROSPECTIVE COHORT STUDY
por: Quan, Joshua, et al.
Publicado: (2022)

788 INCREASE IN ALCOHOLIC HEPATITIS CASES DURING COVID PANDEMIC IN THE US
por: Nair, Geethu G., et al.
Publicado: (2021)

Mo1054: DIAGNOSTIC STRATEGIES FOR HELICOBACTER PYLORI IN PATIENTS WITH BLEEDING PEPTIC ULCERS UNDERGOING ENDOSCOPY: A COST-EFFECTIVENESS ANALYSIS
por: Artin, Michael G., et al.
Publicado: (2022)

Fr136 CENTER-BASED EXPERIENCES IMPLEMENTING STRATEGIES TO REDUCE RISK OF HORIZONTAL TRANSMISSION OF SARS-COV-2: POTENTIAL FOR COMPROMISE OF NEONATAL MICROBIOME ASSEMBLAGE
por: Romano-Keeler, Joann, et al.
Publicado: (2021)

Su1480: TREATMENT-EMERGENT COVID-19 INFECTIONS IN OZANIMOD ULCERATIVE COLITIS AND MULTIPLE SCLEROSIS CLINICAL TRIALS
por: Ungaro, Ryan C., et al.
Publicado: (2022)

Sa112 VENTILATED N95 RESPIRATORS REDUCE CO2 REBREATHING AND HAVE BETTER ACCEPTABILITY
por: Chesta, Fnu, et al.
Publicado: (2021)

Fr134 SARS-COV-2 INDUCES EPITHYELIAL-NEURONAL CROSSTALK STIMULATING VASOACTIVE INTESTINAL PEPTIDE RELEASE AS A POTENTIAL MECHANISM OF COVID-19-ASSOCIATED DIARRHEA
por: He, Peijian, et al.
Publicado: (2021)

Fr230 EFFECT ON EARLY GROWTH OF OFFSPRING BY UNDIAGNOSED MATERNAL CELIAC DISEASE IN PREGNANCY
por: Choung, Rok Seon, et al.
Publicado: (2021)

427 AEROSOL MODELING AND MITIGATION STRATEGIES
por: Jaruvongvanich, Veeravich, et al.
Publicado: (2021)

Sa1273: ENTERIC NEURONAL VASOACTIVE INTESTINAL PEPTIDE MEDIATES SARS-COV-2 ASSOCIATED DIARRHEA
por: Balasubramaniam, Arun, et al.
Publicado: (2022)

Su1488: WITHIN 6 MONTHS FROM COVID-19 BNT162B2 VACCINE PATIENTS WITH INFLAMMATORY BOWEL DISEASES TREATED WITH ANTI-TNFα HAVE SIGNIFICANTLY LOWER SEROLOGIC RESPONSES
por: Rabinowitz, Keren M., et al.
Publicado: (2022)

Su1492: STRONG HUMORAL IMMUNE RESPONSE TO SARS-COV-2 VACCINE ADDITIONAL DOSE AMONG PATIENTS WITH INFLAMMATORY BOWEL DISEASES
por: Kappelman, Michael, et al.
Publicado: (2022)

Su1067: LIVER ENZYMES ALTERATION BUT NOT GI SYMPTOMS ARE ASSOCIATED WITH DEATH IN MINORITY COVID-19 PATIENTS WITH CANCER
por: Oskrochi, Gholamreza, et al.
Publicado: (2022)

Fr004 GASTROINTESTINAL MANIFESTATIONS OF COVID-19 IN ICU AND NON-ICU PATIENTS: A MULTI-CENTER COHORT STUDY
por: Patel, Ankur, et al.
Publicado: (2021)

Fr007 GASTROINTESTINAL MANIFESTATIONS OF COVID-19 ACROSS THE UNITED STATES: A MULTI-CENTER COHORT STUDY
por: Patel, Ankur, et al.
Publicado: (2021)

1165: SARS-COV-2 VACCINATION INDUCES A PREDOMINENTLY CLASS II (CYTOKINE EFFECTOR) T CELL RESPONSE, BUT THE CLASS I RESPONSE IS AUGMENTED BY ANTI-TNF THERAPY AND VACCINE TYPE
por: Xu, Alexander, et al.
Publicado: (2022)

Mo1018: THE T-CELL RESPONSE TO SARS-COV-2 VACCINATION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE IS OFTEN DEFICIENT IN ANTIBODY-RESPONDERS, AND AUGMENTED BY ANTI-TNF THERAPY
por: Li, Dalin, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_k6edehi7svf07tcoig6a0eqaq4